|
Treatment terminations for ineffectiveness in original and re-employed methotrexate therapies |
||||
| Re-employed course |
Total |
|||
|
|
||||
| No inefficacy |
Inefficacy |
|||
|
|
||||
| Original course |
No inefficacy |
19 (9.7 ± 3.1/11.4 ± 4.9) |
9 (10.0 ± 4.0/15.8 ± 6.5) |
28 (9.8 ± 3.3/12.9 ± 5.8) |
| Inefficacy |
23 (11.8 ± 4.5/16.8 ± 5.6) |
28 (14.5 ± 5.3/18.8 ± 5.2) |
51 (13.3 ± 5.1/17.9 ± 5.4) |
|
| Total |
42 (10.9 ± 4.1/14.4 ± 5.9) |
37 (13.5 ± 5.3/18.1 ± 5.6) |
79 (12.1 ± 4.8/16.1 ± 6.0) |
|
|
The numbers in parentheses are the doses in the original methotrexate/re-employed methotrexate courses (mean ± standard deviation) in mg/week). The percentage of patients who were concordant for the presence or absence of inefficacy was 60.3% (P = 0.022, by McNemar test). | ||||
Kapral et al. Arthritis Research & Therapy 2006 8:R46 doi:10.1186/ar1902 |
||||